Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma

Authors:

Abstract
Beta-1,3-glucuronosyltransferase (B3GAT3), overexpressed in hepatocellular carcinoma (HCC) and negatively correlated to prognosis, is a promising target for cancer therapy. Currently, no studies have reported small molecule inhibitors of B3GAT3. In this study, we designed and synthesized a series of small-molecule inhibitors of B3GAT3 through virtual screening and structure optimization. The lead compound TMLB-C16 exhibited potent B3GAT3 inhibitory activity (KD = 3.962 mu M) by effectively suppressing proliferation and migration, and inducing cell cycle arrest and apoptosis in MHCC-97H (IC50= 6.53 +/- 0.18 mu M) and HCCLM3 (IC50= 6.22 +/- 0.23 mu M) cells. Furthermore, compound TMLB-C16 demonstrated favorable pharmacokinetic properties with a relatively high bioavailability of 68.37%. It significantly inhibited tumor growth in both MHCC-97H and HCCLM3 xenograft tumor models without causing obvious toxicity. These results indicate that compound TMLB-C16 is an effective small molecule inhibitor of B3GAT3, providing a basis for the future development of B3GAT3-targeted drugs.
Funding Information
  • State Key Laboratory of Natural Medicines (SKLNMZZ202309)
  • China Pharmaceutical University (2632023GR25, 3012300091)
  • Natural Science Foundation of Jiangsu Province (BK20210428)
  • Science Fund for Distinguished Young Scholars of Jiangsu Province (7032300014-001)
  • National Natural Science Foundation of China (82002971, 82104232, 82330119)
  • Jiangsu Provincial Outstanding Postdoctoral Program (1412300102)

This publication has 46 references indexed in Scilit: